

# Nitrosamine Mitigation Strategies: Insights from the FDA and Emerging Challenges

**Diaa Shakleya, Ph.D., Senior Research Scientist**

Division of Pharmaceutical Quality Research  
DPQRV/OPQR/OPQ/CDER/FDA

[FY2026 GDUFA Public Workshop] – June 8-9, 2026

Everyone deserves confidence in  
their *next* dose of medicine.


Pharmaceutical quality  
assures the  
availability,  
safety,  
and efficacy  
of *every* dose.

# Disclaimer

***“This presentation is not intended to convey formal FDA policy.”***

# Presentation Outline

- ❖ Root Causes of Nitrosamine Contamination
- ❖ Control Strategies
- ❖ Mitigation Strategies: FDA Insights
- ❖ Mitigation Challenges



# Key Root Causes Across the Product Lifecycle

**Manufacturing Process:** Reactions, solvents, and processing conditions may create nitrosamines.

**Raw Materials:** APIs or excipients may contain impurities or precursors.

**Storage & Degradation:** Heat, moisture, and shelf life may promote formation over time.

**Cross-Contamination:** Shared equipment or inadequate cleaning may introduce contamination.

**Process Changes:** Supplier change, or scale-up changes can introduce new risks.

**Key Takeaway:** Nitrosamine contamination can arise from multiple stages, requiring a systematic risk-based assessment.

# Control Strategies

## API Manufacturing Controls & Nitrosamine Risk Mitigation

### Supplier Qualification

Qualification program considering potential nitrite impurities across excipient suppliers and lots to reduce nitrosamine formation risk.

### Antioxidants & pH Modifiers

Use of Vitamin C, Vitamin E, sodium carbonate, and related agents to minimize degradation and impurity formation.

### Manufacturing Controls

Enhanced blending, drying, and process controls to maintain consistent product quality.

### Packaging Controls

Protective packaging strategies to preserve product stability and minimize contamination risk.

# Mitigation Strategies for Nitrosamine Formation

FDA Insights | OPQR Research Findings

## Antioxidants

- Effective inhibitors for reducing nitrosamine impurities
- Top performers: Ascorbic acid, Caffeic acid, and Ferulic acid
- Intercept reactive species before they attack amine groups


## pH Control

- Acidic conditions facilitate nitrosating reactions
- Neutral pH reduces the formation of reactive nitrosating agents
- Creates an unfavorable environment for nitrosamine formation

## Heat & Moisture Control

- Elevated heat and moisture increase nitrosamine formation
- Wet granulation drying may create conversion hotspots
- Careful drying parameter control is critical

# Experimental Workflow






# Nitrosobumetanide Formation – Screening Study



Nitrosamine Formation by Excipient and Storage Condition



- **Avicel PH101 and combined excipients** showed the highest nitrosamine formation under stress conditions.
- **Minimal increases** were observed with magnesium stearate.
- **Elevated temperature and humidity** significantly accelerated impurity formation.
- **Placebo and individual excipients alone** showed negligible nitrosamine content.

# In-House Drug Formulations



| Basic Formulation           |                         |
|-----------------------------|-------------------------|
| Ingredient                  | (%)                     |
| <b>Intra-granular</b>       |                         |
| Metformin                   | 70.4                    |
| Antioxidant                 | 0, 0.1, 0.5, 1          |
| <b>Granulation (binder)</b> |                         |
| Povidone K-30               | 3.52                    |
| Water                       | 10 (to the whole batch) |
| Nitrite/DMA                 | 0, 100 ppm              |
| <b>Extra-granular</b>       |                         |
| Hypromellose                | 16.9                    |
| Crospovidone XL-10          | 4.22                    |
| Avicel PH-102               | 3.52                    |
| C. Silicon Dioxide          | 0.7                     |
| Magnesium Stearate          | 0.7                     |
| Total                       | 100                     |




| Formulation # | Antioxidant   | Percentage of Antioxidant (%) | Nitrite (100 ppm) | Formulation                                                             |
|---------------|---------------|-------------------------------|-------------------|-------------------------------------------------------------------------|
| 1             | ---           | ---                           | ---               | Control                                                                 |
| 2             | ---           | ---                           | Spiked            | Nitrite Spiked Control                                                  |
| 3             | ---           | ---                           | Spiked            | DMA Spiked Control                                                      |
| 4             | ---           | ---                           | Spiked            | Nitrite+DMA Spiked Control                                              |
| 5             | Ascorbic Acid | 0.1                           | N/A               | Antioxidant effect on nitrite spiked and non-spiked formulations        |
| 6             |               |                               | Spiked            |                                                                         |
| 7             |               | 0.5                           | N/A               |                                                                         |
| 8             |               |                               | Spiked            |                                                                         |
| 9             | Caffeic Acid  | 1                             | N/A               |                                                                         |
| 10            |               |                               | Spiked            |                                                                         |
| 11            |               | 0.1                           | N/A               |                                                                         |
| 12            |               |                               | Spiked            |                                                                         |
| 13            | Ferulic Acid  | 0.5                           | N/A               |                                                                         |
| 14            |               |                               | Spiked            |                                                                         |
| 15            |               | 1                             | N/A               |                                                                         |
| 16            |               |                               | Spiked            |                                                                         |
| 17            | None          | 0.1                           | N/A               |                                                                         |
| 18            |               |                               | Spiked            |                                                                         |
| 19            |               | 0.5                           | N/A               |                                                                         |
| 20            |               |                               | Spiked            |                                                                         |
| 21            | None          | 1                             | N/A               |                                                                         |
| 22            |               |                               | Spiked            |                                                                         |
| 23            |               |                               | N/A               | Acidic pH Modifier (pH=3)                                               |
| 24            |               |                               | Spiked            |                                                                         |
| 25            | None          |                               | N/A               | Basic pH Modifier (pH=8-9)                                              |
| 26            |               |                               | Spiked            |                                                                         |
| 27            |               |                               | N/A               | Original Formulation without Povidone K-30 (Binder)                     |
| 28            |               |                               | Spiked            | Original Formulation without Povidone K-30 (Binder); Nitrite/DMA spiked |



| EVALUATED FACTORS                 |                                                                                       |
|-----------------------------------|---------------------------------------------------------------------------------------|
| Antioxidant Type                  | Ascorbic Acid<br>Caffeic Acid<br>Ferulic Acid                                         |
| Antioxidant Level                 | 0.10%<br>0.50%<br>1.00%                                                               |
| Effect of spiking nitrite and DMA | Zero<br>100 ppm                                                                       |
| Effect of pH                      | Acidic pH = 3.00<br>Basic pH = 8.00                                                   |
| Moisture and heat                 | 60% water<br>60°C<br>Heated air                                                       |
| Stability Conditions              | 50°C/75% RH 1 month<br>40°C/75% RH 1, 2, 3, 6 months<br>25°C/60% RH 1, 2, 3, 6 months |

# % of Inhibition Efficiency by The Antioxidants

## (6-Month Stability of Bumetanide Tablets)



# NDSRI Mitigation Challenges

## Analytical Challenges

- Detection limits & sensitive instrumentation
- Matrix interference
- Lack of reference standards
- In-situ nitrosamine formation



**NDSRI**  
Risk  
Mitigation



## Manufacturing & Process Challenges

- API stability
- Multiple formation pathways
- Antioxidant selection

## Mitigation Workflow

Raw Materials



Process Control



Analytical Testing



Risk Reduction

# Key strategies to reduce nitrosamine formation in pharmaceutical products

## Antioxidant Optimization

Tailored antioxidants significantly reduced nitrosamine formation, highlighting the importance of formulation-specific mitigation strategies.

## pH Management

Neutral pH conditions and sodium carbonate effectively minimized nitrosation reactions, demonstrating pH control as a critical preventive measure.

## Process & Lifecycle Control

Robust raw material oversight, optimized manufacturing conditions, and continuous monitoring are essential to sustain nitrosamine risk mitigation.

**Integrated formulation design, pH optimization, and manufacturing controls collectively provide the strongest defense against nitrosamine formation.**

# Acknowledgments

- OPQR Colleagues
- OPQR Management
- OPQ Nitrosamine WG
- 2026 GDUFA Workshop Committee

